These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 15692505

  • 1. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis.
    Nadiminti U, Arbiser JL.
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):17-9. PubMed ID: 15692505
    [Abstract] [Full Text] [Related]

  • 2. [Rapamycin: a new immunosuppressive agent capable of inhibiting chronic rejection?].
    Viklický O, Matl I.
    Cas Lek Cesk; 2001 Jan 19; 140(1):22-5. PubMed ID: 11242980
    [Abstract] [Full Text] [Related]

  • 3. Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases.
    Tsagalis G, Psimenou E, Iliadis A, Nakopoulou L, Laggouranis A.
    Am J Kidney Dis; 2009 Aug 19; 54(2):340-4. PubMed ID: 19303679
    [Abstract] [Full Text] [Related]

  • 4. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.
    Expert Opin Drug Saf; 2009 Jul 19; 8(4):421-34. PubMed ID: 19522662
    [Abstract] [Full Text] [Related]

  • 5. Multiple eruptive dermatofibromas in a patient with dermatomyositis taking prednisolone and methotrexate.
    Huang PY, Chu CY, Hsiao CH.
    J Am Acad Dermatol; 2007 Nov 19; 57(5 Suppl):S81-4. PubMed ID: 17097372
    [Abstract] [Full Text] [Related]

  • 6. Disseminated Nocardia brasiliensis infection: an unusual complication of immunosuppressive treatment for childhood dermatomyositis.
    Klein-Gitelman MS, Szer IS.
    J Rheumatol; 1991 Aug 19; 18(8):1243-6. PubMed ID: 1941833
    [Abstract] [Full Text] [Related]

  • 7. Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma.
    Hansen CB, Callen JP.
    Dermatol Ther; 2010 Aug 19; 23(4):341-9. PubMed ID: 20666821
    [Abstract] [Full Text] [Related]

  • 8. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.
    Kaposztas Z, Etheridge WB, Kahan BD.
    Transplant Proc; 2008 Jun 19; 40(5):1744-6. PubMed ID: 18589184
    [Abstract] [Full Text] [Related]

  • 9. Azoospermia in a renal transplant recipient during sirolimus (rapamycin) treatment.
    Skrzypek J, Krause W.
    Andrologia; 2007 Oct 19; 39(5):198-9. PubMed ID: 17714220
    [Abstract] [Full Text] [Related]

  • 10. Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome.
    Janić MD, Brasanac CD, Janković JS, Dokmanović BL, Krstovski RN, Kraguljac Kurtović JN.
    Pediatr Blood Cancer; 2009 Dec 19; 53(6):1117-9. PubMed ID: 19588524
    [Abstract] [Full Text] [Related]

  • 11. Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
    Sereda D, Werth VP.
    Arch Dermatol; 2006 Jan 19; 142(1):70-2. PubMed ID: 16415389
    [Abstract] [Full Text] [Related]

  • 12. Sirolimus--challenging current perspectives.
    Buhaescu I, Izzedine H, Covic A.
    Ther Drug Monit; 2006 Oct 19; 28(5):577-84. PubMed ID: 17038868
    [Abstract] [Full Text] [Related]

  • 13. [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].
    Roque E J, Ríos M G, Vignolo A P, Pinochet V C, Schultz M, Humeres A R, Delucchi A, Rius A M, Hepp K J.
    Rev Med Chil; 2008 May 19; 136(5):631-6. PubMed ID: 18769812
    [Abstract] [Full Text] [Related]

  • 14. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
    Iaria G, Anselmo A, De Luca L, Manuelli M, Lucchesi C, Tariciotti L, Monaco A, Sforza D, Nigro F, Abruzzese E, Tisone G.
    Transplant Proc; 2007 May 19; 39(6):2036-7. PubMed ID: 17692685
    [Abstract] [Full Text] [Related]

  • 15. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment.
    Ramos-Barrón A, Piñera-Haces C, Gómez-Alamillo C, Santiuste-Torcida I, Ruiz JC, Buelta-Carrillo L, Merino R, de Francisco AL, Arias M.
    Lupus; 2007 May 19; 16(10):775-81. PubMed ID: 17895299
    [Abstract] [Full Text] [Related]

  • 16. Management of side effects of sirolimus therapy.
    Stallone G, Infante B, Grandaliano G, Gesualdo L.
    Transplantation; 2009 Apr 27; 87(8 Suppl):S23-6. PubMed ID: 19384183
    [Abstract] [Full Text] [Related]

  • 17. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, Ma MM, Mason AL, Wong WW, Bain VG, Kneteman NM.
    Transplantation; 2007 May 15; 83(9):1162-8. PubMed ID: 17496530
    [Abstract] [Full Text] [Related]

  • 18. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients.
    Celik S, Doesch A, Erbel C, Blessing E, Ammon K, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2008 Jul 27; 86(2):245-50. PubMed ID: 18645486
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease.
    Couriel DR, Saliba R, Escalón MP, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima MJ, Andersson B, Neumann J, Champlin R.
    Br J Haematol; 2005 Aug 27; 130(3):409-17. PubMed ID: 16042691
    [Abstract] [Full Text] [Related]

  • 20. Sirolimus (rapamycin): from the soil of Easter Island to a bright future.
    Paghdal KV, Schwartz RA.
    J Am Acad Dermatol; 2007 Dec 27; 57(6):1046-50. PubMed ID: 17583372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.